Novel technology for producing High-affinity monoclonal antibodies (GANP gene modified mouse)

Our high-affinity antibody technology (GANP® technology) has been introduced in the Japanese version of weekly scientific journal, NATURE (Vol. 439, No. 7078,published on February 16^th2006).

We have started the new business with GANP (germinal center associated nuclear protein) gene modified mice, by obtaining an exclusive license to produce high-affinity antibodies.

1. GANP gene and its technology (PCT/JP03/14221) were invented by Prof. N. Sakaguchi from Kumamoto University, and Immunokick Incorporation has their rights. TRANS GENIC INC. has obtained the exclusive licenses from Immunokick, and put them  into business.
   
2. A GANP gene modified Mouse is much-anticipated for applications in the fields of pharmaceutical products, diagnostic products, assay systems with antibodies, and research reagents, since they make it possible to produce monoclonal antibodies with remarkably higher affinities than it was possible then. 
   

We plan to apply the technology for the purposes below, although the detailed business model is still under consideration.

1. Collaborative researches with pharmaceutical companies towards an application for pharmaceutical products.
2. Collaborative researches and developments towards an application for diagnostic products.
3. Production of antibodies as research reagents and the production service of monoclonal antibodies to your order.